

52. Katodritou E., Terpos E., Zervas K. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. *Ann Hematol* 2007;86(5):369–76.
53. Romanenko N.A., Golovtshenko R.A., Kostroma I.I., Abdulkadyrov K.M. Study of efficacy recombinant human erythropoietin in multiple myeloma patients with anemia. *Haematologica* 2012;97(Suppl. 1):622.
54. Richardson P., Schlag R., Khuageva N. et al. Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. *Br J Haematol* 2011; 153(2):212–21.
55. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. *Oncologist* 2011;16(Suppl. 3): 35–42.
56. Villegas A., Arrizabalaga B., Fernández-Lago C. et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. *Curr Med Res Opin* 2011; 27(5):951–60.
57. Park S., Kelaidi C., Sapena R. et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. *Leuk Res* 2010;34(11):1430–6.
58. Cervantes F., Alvarez-Larrán A., Hernández-Boluda J.C. et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. *Br J Haematol* 2004;127(4):399–403.
59. Nagel S., Kellner O., Engel-Riedel W. et al. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. *Clin Lung Cancer* 2011; 12(1):62–9.
60. Eisterer W., Hussl C., Erb H. et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. *Curr Med Res Opin* 2011; 27(2):355–63.
61. Steensma D.P., Sloan J.A., Dakhil S.R. et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. *J Clin Oncol* 2011;29(1):97–105.
62. Ludwig H., Crawford J., Osterborg A. et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. *J Clin Oncol* 2009;27(17):2838–47.
63. Vansteenkiste J., Glaspy J., Henry D. et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. *Lung Cancer* 2012;76(3):478–85.
64. Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. *J Clin Oncol* 2008;26(10):1611–8.
65. Katodritou E., Speletas M., Zervas K. et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. *Lab Hematol* 2006;12(1):47–54.